{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:08:11Z","timestamp":1790165291098,"version":"4.1.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk AS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.rpth.2026.106820","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T23:33:02Z","timestamp":1785195182000},"page":"106820","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired hemophilia A: an illustrated review based on the French National Guidelines"],"prefix":"10.1016","volume":"10","author":[{"given":"Beno\u00eet","family":"Guillet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseline","family":"d\u2019Oiron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastien","family":"Lacroix-Desmazes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Chamouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Aouba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Castet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ygal","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Nougier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Noel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Repesse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Graveleau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Trossaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"L\u00e9vesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4888-1463","authenticated-orcid":false,"given":"Yesim","family":"Dargaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2026.106820_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101320","article-title":"Current trends and advances in the management of acquired Hemophilia A","volume":"74","author":"Zuner","year":"2025","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2026.106820_bib2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1538-7836.2012.04654.x","article-title":"Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"10","author":"Knoebl","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib3","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1182\/blood-2006-06-029850","article-title":"Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors\u2019 Organisation","volume":"109","author":"Collins","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib4","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1471-0528.2012.03469.x","article-title":"Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry","volume":"119","author":"Tengborn","year":"2012","journal-title":"BJOG"},{"key":"10.1016\/j.rpth.2026.106820_bib5","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/hae.12138","article-title":"Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l\u2019H\u00e9mophilie Acquise) registry","volume":"19","author":"Borg","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/bjh.16128","article-title":"Outcome of CARE: a 6-year national registry of acquired haemophilia A in China","volume":"187","author":"Sun","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106820_bib7","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.1182\/bloodadvances.2021004626","article-title":"Management of acquired hemophilia A: results from the Spanish registry","volume":"5","author":"Mingot-Castellano","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106820_bib8","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/bjh.18611","article-title":"Acquired Haemophilia A in four north European countries: survey of 181 patients","volume":"201","author":"Lindahl","year":"2023","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106820_bib9","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/bjh.19285","article-title":"Acquired haemophilia A in paediatric patients: a retrospective French cohort of eight cases","volume":"204","author":"Mouthon","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2026.106820_bib10","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/pbc.22657","article-title":"Acquired hemophilia in pediatrics: a systematic review","volume":"55","author":"Franchini","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.rpth.2026.106820_bib11","article-title":"Time is blood: the impact of diagnostic delays on acquired hemophilia A","volume":"14","author":"Fragner","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.rpth.2026.106820_bib12","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/blood-2016-11-751347","article-title":"Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A","volume":"130","author":"Kahle","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib13","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1160\/TH08-08-0508","article-title":"Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains","volume":"101","author":"Gharagozlou","year":"2009","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib14","doi-asserted-by":"crossref","first-page":"3663","DOI":"10.1182\/blood.V89.10.3663","article-title":"The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups","volume":"89","author":"Prescott","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib15","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.jtha.2024.02.016","article-title":"Comprehensive domain-specific analysis and immunoglobulin G profiling of anti\u2013factor VIII antibodies using a bead-based multiplex immunoassay","volume":"22","author":"Pezeshkpoor","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1182\/blood.V95.1.156","article-title":"A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor","volume":"95","author":"Jacquemin","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib17","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/blood.V97.3.669","article-title":"Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis","volume":"97","author":"Nogami","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib18","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1055\/s-0034-1390004","article-title":"Laboratory diagnosis of acquired hemophilia A: limitations, consequences, and challenges","volume":"40","author":"Tiede","year":"2014","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106820_bib19","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/MBC.0000000000000582","article-title":"Assessment of acquired hemophilia patient demographics in the United States: the Hemostasis and Thrombosis Research Society Registry","volume":"27","author":"Kessler","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106820_bib20","article-title":"Acquired hemophilia A in a woman with systemic lupus erythematosus: a case report and review of literature","volume":"99","author":"Shen","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rpth.2026.106820_bib21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/hae.13355","article-title":"Acquired haemophilia in cancer: a systematic and critical literature review","volume":"24","author":"Napolitano","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib22","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.14692","article-title":"Drug-associated acquired hemophilia A: an analysis based on 185 cases from the WHO pharmacovigilance database","volume":"29","author":"Konstantinov","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib23","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.revmed.2022.04.012","article-title":"Acquired hemophilia and pregnancy: a necessarily multidisciplinary approach","volume":"43","author":"L\u00e9vesque","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.rpth.2026.106820_bib24","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/hae.13844","article-title":"Clinical evaluation of bleeds and response to haemostatic treatment in patients with acquired haemophilia: a global expert consensus statement","volume":"25","author":"Tiede","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib25","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000005232","article-title":"Influence of factor VIII level and its inhibitor titer on the therapeutic response to corticosteroids alone in the management of acquired hemophilia: a retrospective single-center study","volume":"95","author":"Vautier","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.rpth.2026.106820_bib26","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib27","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.revmed.2021.07.003","article-title":"Characterizing hospital pathways for the care of acquired hemophilia in France using comprehensive national health data","volume":"43","author":"Guillet","year":"2022","journal-title":"Rev Med Interne"},{"key":"10.1016\/j.rpth.2026.106820_bib28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2023.11.025","article-title":"Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong","volume":"233","author":"Sin","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106820_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102565","article-title":"Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI study","volume":"8","author":"Burgmann","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib30","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.3324\/haematol.2019.230771","article-title":"International recommendations on the diagnosis and treatment of acquired hemophilia A","volume":"105","author":"Tiede","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106820_bib31","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2012-02-408930","article-title":"Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry","volume":"120","author":"Baudo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.tru.2020.100021","article-title":"Adaptation of recombinant activated factor VII in the treatment of acquired haemophilia A: results from a prospective study (ACQUI-7) in France","volume":"2","author":"Guillet","year":"2021","journal-title":"Thrombosis Update"},{"key":"10.1016\/j.rpth.2026.106820_bib33","first-page":"279","article-title":"Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01\/2010 study","volume":"136","author":"Holstein","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/MBC.0000000000000471","article-title":"Use of recombinant activated factor VII for acute bleeding episodes in acquired hemophilia: final analysis from the Hemostasis and Thrombosis Research Society Registry acquired hemophilia study","volume":"27","author":"Ma","year":"2016","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.rpth.2026.106820_bib35","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/hae.12574","article-title":"FEIBA in the treatment of acquired haemophilia A: results from the prospective multicentre French \u2018FEIBA dans l\u2019h\u00e9mophilie A acquise\u2019 (FEIBHAC) registry","volume":"21","author":"Borg","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib36","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2516.2012.02748.x","article-title":"Combined treatment with APCC (FEIBA\u00ae) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience","volume":"18","author":"Holmstrom","year":"2012","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib37","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/hae.12627","article-title":"Efficacy and safety of OBI-1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A","volume":"21","author":"Kruse-Jarres","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/hae.13040","article-title":"Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients","volume":"23","author":"Tarantino","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib39","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/S2352-3026(23)00280-6","article-title":"Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study","volume":"10","author":"Tiede","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.rpth.2026.106820_bib40","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.jtha.2022.10.004","article-title":"A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A","volume":"21","author":"Shima","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib41","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1016\/j.jtha.2024.06.010","article-title":"Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia A","volume":"22","author":"Hart","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib42","doi-asserted-by":"crossref","first-page":"5896","DOI":"10.1182\/bloodadvances.2024013882","article-title":"Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort","volume":"8","author":"Poston","year":"2024","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106820_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102438","article-title":"Emicizumab as first-line therapy in acquired hemophilia A","volume":"8","author":"Iarossi","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.bvth.2024.100027","article-title":"Clinical characteristics and outcomes of acquired hemophilia A before and after emicizumab approval in Japan","volume":"1","author":"Kishi","year":"2024","journal-title":"Blood Vessel Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106820_bib45","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1055\/a-2384-3585","article-title":"Final analysis results from the AGEHA study: emicizumab prophylaxis for acquired hemophilia A with or without immunosuppressive therapy","volume":"125","author":"Shima","year":"2025","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib46","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1182\/bloodadvances.2025017144","article-title":"Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A","volume":"9","author":"Schimansky","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.rpth.2026.106820_bib47","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.jtha.2024.09.040","article-title":"Acquired hemophilia A: a narrative review and management approach in the emicizumab era","volume":"23","author":"Ellsworth","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.rpth.2026.106820_bib48","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1080\/17474086.2024.2352505","article-title":"Inhibitor eradication and treatment for acquired hemophilia A","volume":"17","author":"Franchini","year":"2024","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.rpth.2026.106820_bib49","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2012-02-409185","article-title":"Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2)","volume":"120","author":"Collins","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib50","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2002-03-0765","article-title":"Rituximab in the treatment of acquired factor VIII inhibitors","volume":"100","author":"Wiestner","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2026.106820_bib51","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3324\/haematol.10553","article-title":"Rituximab for the treatment of acquired antibodies to factor VIII","volume":"92","author":"Sperr","year":"2007","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2026.106820_bib52","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00277-020-04150-y","article-title":"Reduced-intensity, risk factor-stratified immunosuppression for acquired hemophilia A: single-center observational study","volume":"99","author":"Dobbelstein","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.rpth.2026.106820_bib53","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/ejh.13708","article-title":"A low-dose rituximab regimen for first-line treatment of acquired haemophilia A","volume":"108","author":"Hunt","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.rpth.2026.106820_bib54","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/ajh.27128","article-title":"Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: a multicenter, open-label, randomized noninferiority trial","volume":"99","author":"Wang","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106820_bib55","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.thromres.2024.03.012","article-title":"Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: a randomized trial in 108 patients","volume":"237","author":"Levesque","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2026.106820_bib56","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/hae.13752","article-title":"The factor VIII:C\/VWF:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: a retrospective cohort study","volume":"25","author":"Trossaert","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2026.106820_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<1::AID-AJH1>3.0.CO;2-T","article-title":"Postpartum acquired factor VIII inhibitors: results of a survey","volume":"59","author":"Solymoss","year":"1998","journal-title":"Am J Hematol"},{"key":"10.1016\/j.rpth.2026.106820_bib59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1177\/107602960000600206","article-title":"Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment","volume":"6","author":"Michiels","year":"2000","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.rpth.2026.106820_bib60","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/hae.14233","article-title":"Acquired haemophilia A in the postpartum and risk of relapse in subsequent pregnancies: a systematic literature review","volume":"27","author":"Dewarrat","year":"2021","journal-title":"Haemophilia"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034783?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037926034783?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:55:51Z","timestamp":1790164551000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037926034783"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":59,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2475037926034783"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106820","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acquired hemophilia A: an illustrated review based on the French National Guidelines","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2026.106820","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"106820"}}